3 completed, 3 enrolling by invitation, 3 terminated. 2 Not applicable, 2 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Terminated 1 |
| Phase 1 | 2 | Enrolling by invitation 1, Terminated 1 |
| Phase 2 | 2 | Enrolling by invitation 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Genes: new trials by email Literature Review of Genes trials Research Report on Genes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease Busulfan, Tocilizumab, Eltrombopag - Chronic Granulomatous Disease (CGD) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2025-09-10 | 2026-09-08 |
| TRIM25 in Septic Patients Gene and Inflammatory Marker Analysis in Sepsis - Sepsis | Enrolling by invitation | Ruijin Hospital | 65 | 2021-12-10 | 2026-01-06 | |
| Alcohol Metabolism and Disease Risk in Asians Phenotype Feedback Intervention, Genotype Feedback Intervention - Healthy | Not applicable | Completed | University of Southern California | 360 | 2021-08-18 | 2024-12-24 |
| An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV) - Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID) | Enrolling by invitation | University of California, Los Angeles | 70 | 2019-09-26 | 2025-12-18 | |
| Performance Determinants Factors in Elite Endurance Athletes. Age, Genes, Training, Tickbourne Disease and Endurance - Exercise Physiology | Completed | University of South-Eastern Norway | 54 | 2018-06-27 | 2022-08-04 | |
| Prospective Prolaris Value and Efficacy Prolaris - Prostate Cancer | Terminated | Myriad Genetic Laboratories, Inc. | 1511 | 2015-09-01 | 2022-06-13 | |
| Pharmacotoxicology of Trichloroethylene Metabolites Dichloroacetate, Genotyping, Leucine - Healthy | Not applicable | Terminated | University of Florida | 2 | 2011-08-01 | 2015-06-03 |
| High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC) - AIDS-related Lymphoma, HIV Infections | Phase 1 / Phase 2 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 5 | 2008-11-28 | 2022-09-08 |
| Genetic Study of Age Related Hearing Loss genes - Age-related Hearing Loss, Presbycusis | Early Phase 1 | Completed | National Taiwan University Hospital | 1000 | 2008-08-01 | 2012-11-22 |
Acquired Immunodeficiency Syndrome (1) · Granulomatous Disease, Chronic (1) · HIV Infections (1) · Lymphoma (1) · Lymphoma, AIDS-Related (1) · Presbycusis (1) · Prostatic Neoplasms (1) · Sepsis (1) · Severe Combined Immunodeficiency (1) · Severe combined immunodeficiency due to adenosine deaminase deficiency (1)
Myriad Genetic Laboratories, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Taiwan University Hospital (1) · Ruijin Hospital (1) · University of California, Los Angeles (1) · University of Florida (1) · University of South-Eastern Norway (1) · University of Southern California (1) · Universitätsklinikum Hamburg-Eppendorf (1)
United States (5) · China (1) · Germany (1) · Norway (1) · Taiwan (1) · United Kingdom (1)
Donald B. Kohn, M.D. (1) · Elizabeth M Kang, M.D. (1) · Nicolaus Kroeger (1) · Peter W Stacpoole, PhD, MD (1) · Susan E. Luczak, Ph.D. (1) · Tien-Chen Liu, MD, PhD (1)
PMID 21289631, PMID 41092330, PMID 42310974
R01ES014617 (1)